Hims says it will stop selling GLP-1 pill, after legal pressure from USnews2026-02-07T20:24:40+00:00February 7th, 2026|Endpoints News|
US calls for DOJ investigation of Hims over GLP-1 drugsnews2026-02-06T23:08:43+00:00February 6th, 2026|Endpoints News|
TrumpRx launch falls flat for some, citing generic accessnews2026-02-06T21:01:47+00:00February 6th, 2026|Endpoints News|
HHS drops legal fight over blocked 340B rebate pilotnews2026-02-06T19:19:31+00:00February 6th, 2026|Endpoints News|
Biogen CEO says Alzheimer’s drug Leqembi on track for continued growthnews2026-02-06T16:11:57+00:00February 6th, 2026|Endpoints News|
Post-Hoc Live: Analyzing the Novo vs. Hims GLP-1 showdownnews2026-02-06T12:00:29+00:00February 6th, 2026|Endpoints News|
FDA chief Makary takes aim at Hims’ compounded Wegovy pill plansnews2026-02-05T23:52:28+00:00February 5th, 2026|Endpoints News|
Novo’s threat to sue Hims over Wegovy pill faces legal hurdlenews2026-02-05T21:25:38+00:00February 5th, 2026|Endpoints News|
#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trialnews2026-02-05T17:15:12+00:00February 5th, 2026|Endpoints News|
